Advertisement: Killer 50 TTP Group
14 November, 2013 - 13:06 By News Desk


definigen, stem cell, cambridge

A leading provider of stem cell products, DefiniGEN is focused on serving the growing need in the pharmaceutical industry for more accurate predictions of efficacy and toxicity in drug candidates ahead of clinical trials.

Its platform technology OptiDIFF is a revolutionary stem cell production platform for the generation of high-functionality cell types including, liver, pancreatic and lung cells. In May 2017, the company strengthened its IP portfolio with a licence for liver cell technology from Cambridge Enterprise, the commercialisation arm of the university.

The technology will be used to develop optimised liver cell products and services for various applications, such as disease modelling, drug screening and therapeutic target validation.


Newsletter Subscription

Stay informed of the latest news and features